Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma

Annals of Surgery

Volumn 244, Issue 5, 2006, Pages 799-804

  Kim, Joseph ^a   Giuliano, Armando E ^a   Turner, Roderick R ^a   Gaffney, Robyn E ^a   Umetani, Naoyuki ^a   Kitago, Minoru ^a   Elashoff, David ^b   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE MAPPING; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; MULTIVARIATE ANALYSIS; PAPILLARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; THYROID CARCINOMA; THYROIDECTOMY; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; DNA, NEOPLASM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SENTINEL LYMPH NODE BIOPSY; THYROID NEOPLASMS;

EID: 33750308218     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000224751.80858.13     Document Type: Article

References (41)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
2. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
3. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003;4:95-98.
4. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003;163:1255-1260.
5. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
6. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567.
7. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell. 2004;116:855-867.
8. Garnett MJ, Marais R. Guilty as charged: BRAF is a human oncogene. Cancer Cell. 2004;6:313-319.
9. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
10. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
11. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397.
12. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
13. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003;9:3362-3368.
14. Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature. 2004;4:718-727.
15. V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005;65:2465-2473.
16. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-B-RAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005;115:1068-1081.
17. Kelemen PR, Van Herle AJ, Giuliano AE. Sentinel lymphadenectomy in thyroid malignant neoplasms. Arch Surg. 1998;133:288-292.
18. Turner RR. Histopathologic processing of the sentinel lymph node. Semin Breast Dis. 2002;5:35-40.
19. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.
20. Catarci M, Zaraca F, Angeloni R, et al. Preoperative lymphoscintigraphy and sentinel lymph node biopsy in papillary thyroid cancer: a pilot study. J Surg Oncol. 2001;77:21-24.
21. Chow TL, Lim BH, Kwok SP. Sentinel lymph node dissection in papillary thyroid carcinoma. ANZ J Surg. 2004;74:10-12.
22. Tsugawa K, Ohnishi I, Nakamura M, et al. Intraoperative lymphatic mapping and sentinel lymph node biopsy in patients with papillary carcinoma of the thyroid gland. Biomed Pharmacother. 2002;55:100-103.
23. Hoon DS, Spugnardi M, Kuo C, et al. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 2004;23:4014-4022.
24. Shinozaki M, Fujimoto A, Morton DL, et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10:1753-1757.
25. Taback B, Bilchik AJ, Saha S, et al. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer. 2004;111:409-414.
26. Mouritzen P, Nielsen AT, Pfundheller HM, et al. Single nucleotide polymorphism genotyping using locked nucleic acid (LNA). Expert Rev Mol Diagn. 2003;3:27-38.
27. McDermott WV Jr, Morgan WS, Hamlin E Jr, et al. Cancer of the thyroid. J Clin Endocrinol Metab. 1954;19:1336-1354.
28. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the EORTC thyroid cancer cooperative group. Eur J Cancer. 1979;15:1033-1041.
29. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1,779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1058.
30. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036-1041.
31. Eichhorn W, Tabler H, Lippold R, et al. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid. 2003;13:949-958.
32. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714-720.
33. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
34. Cady B. Our AMES is true: how an old concept still hits the mark; or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174:462-468.
35. Caron NR, Clark OH. Papillary thyroid cancer: surgical management of lymph node metastases. Curr Treat Options Oncol. 2005;6:311-322.
36. Fukui Y, Yamakawa T, Taniki T, et al. Sentinel lymph node biopsy in patients with papillary thyroid carcinoma. Cancer. 2001;92:2868-2874.
37. Arch-Ferrer J, Velazquez D, Fajardo R, et al. Accuracy of sentinel lymph node in papillary thyroid carcinoma. Surgery. 2001;130:907-913.
38. Yao K, Turner R, Singer F, et al. Sentinel lymph node mapping in thyroid cancer. International Sentinel Node Congress, Yokohama, Japan, November 16-18, 2002.
39. Vasko V, Hu S, Wu G, et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab. 2005;90:5265-5269.
40. Oler G, Ebina KN, Michaluart P Jr, et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol. 2005;62:509-511.
41. Shattuck TM, Westra WH, Ladenson PW, et al. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005;352:2406-2412.